• Dr. Limdi is a clinical pharmacist and epidemiologist with significant expertise in pharmacogenomics and pharmacoepidemiology, from research and discovery to its application and implementation in clinical practice. Her research portfolio encompasses studies with both observational and a clinical trial designs and is focused on understanding the multiple factors that influence drug efficacy and safety, specifically anticoagulant and antiplatelet response. An established investigator in the field of pharmacogenomics, she has made significant contributions towards understanding of genetic basis of warfarin response. Her work has included discovering novel polymorphisms in CYP2C9, statistical analytic approaches that has ranged from candidate gene, haplotype based approach to genome-wide association and exome approaches, and a research portfolio that includes both prospective cohort and randomized clinical trials.

    Through her work, Dr. Limdi has collaborated extensively with pharmacogenomics researchers including with the International Warfarin Pharmacogenomics Consortium (IWPC), the Clinical Pharmacogenetics Implementation Committee (CPIC), and the Implementation of Genomics In pracTicE (IGNITE). As the Associate Director of Pharmacogenomics n the Hugh Kaul Personalized Medicine Institute, Dr. Limdi oversees discovery and clinical implementation of pharmacogenomics across the health UAB system. Through this initiative, her team has identified and overcome barriers, incorporated genotype-guided therapy and assessed clinically relevant outcomes to conduct economic analysis and inform health policy and reimbursement strategies for pharmacogenomics.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Genome-wide meta-analysis of SNP-by9-ACEI/ARB and SNP-by-thiazide diuretic and effect on serum potassium in cohorts of European and African ancestry.Pharmacogenomics Journal.  19:97-108. 2019
    2018 Pharmacogenetics of warfarin dosing in patients of African and European ancestry.Pharmacogenomics.  19:1357-1371. 2018
    2018 Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.Clinical Pharmacology and Therapeutics.  104:664-674. 2018
    2018 Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.  38:588-596. 2018
    2018 Genetic deletion of 12/15 lipoxygenase promotes effective resolution of inflammation following myocardial infarction.Journal of Molecular and Cellular Cardiology.  118:70-80. 2018
    2018 Multisite Investigation of Outcomes With¬†Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.JACC: Cardiovascular Interventions.  11:181-191. 2018
    2017 Racial disparities in temporal lobe epilepsy.Epilepsy Research.  140:56-60. 2017
    2017 Clinical and Genetic Predictors of Delayed Remission After Multiple Levels of Antidepressant Treatment: Toward Early Identification of Depressed Individuals for Advanced Care Options.Journal of Clinical Psychiatry.  78:e1291-e1298. 2017
    2017 Comparison of Two Point-of-Care CYP2C19 Genotyping Assays for Genotype-Guided Antiplatelet Therapy.Annals of Clinical and Laboratory Science.  47:738-743. 2017
    2017 Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.  37:1366-1373. 2017
    2017 Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users.Pharmacogenetics -London-.  27:347-355. 2017
    2017 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.Clinical Pharmacology and Therapeutics.  102:397-404. 2017
    2017 Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.Clinical Pharmacology and Therapeutics.  102:493-501. 2017
    2017 Implementation and utilization of the molecular tumor board to guide precision medicine.Oncotarget.  8:57845-57854. 2017
    2017 Age and Sex Disparities in Discharge Statin Prescribing in the Stroke Belt: Evidence From the Reasons for Geographic and Racial Differences in Stroke Study.Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  6. 2017
    2017 Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.Pharmacogenomics.  18:1059-1073. 2017
    2017 Anticoagulation Control in Patients With Ventricular Assist Devices.ASAIO Journal.  63:759-765. 2017
    2017 Racial differences in statin adherence following hospital discharge for ischemic stroke.Neurology.  88:1839-1848. 2017
    2017 Local Ancestry and Clinical Cardiovascular Events Among African Americans From the Atherosclerosis Risk in Communities Study.Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.  6. 2017
    2017 Admixture Mapping of Subclinical Atherosclerosis and Subsequent Clinical Events Among African Americans in 2 Large Cohort Studies.Circulation: Cardiovascular Genetics.  10. 2017
    2017 The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting.Clinical and Translational Science.  10:143-146. 2017
    2017 Influence of statin therapy at time of stroke onset on functional outcome among patients with atrial fibrillation.International Journal of Cardiology.  227:808-812. 2017
    2017 Genome-wide admixture and association study of subclinical atherosclerosis in the Women's Interagency HIV Study (WIHS).PLoS ONE.  12:e0188725. 2017
    2017 Whole exome analyses to examine the impact of rare variants on left ventricular traits in African American participants from the HyperGEN and GENOA studies.J Hypertens Manag.  3. 2017
    2016 High-Sensitivity C-Reactive Protein and Risk of Stroke in Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke Study).American Journal of Cardiology.  118:1826-1830. 2016
    2016 A systematic analysis and comparison of warfarin initiation strategies.Pharmacogenetics -London-.  26:445-452. 2016
    2016 Pharmacogenetics in Cardiovascular Medicine.Current Genetic Medicine Reports.  4:119-129. 2016
    2016 Differential Impact of Risk Factors in Blacks and Whites in the Development of Atrial Fibrillation: the Reasons for Geographic And Racial Differences in Stroke (REGARDS) Study.Journal of Racial and Ethnic Health Disparities.  4:718-724. 2016
    2016 Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.American Journal of Cardiology.  118:232-236. 2016
    2016 Valvular Heart Disease and Acquired Type 2A von Willebrand Syndrome: The "Hemostatic" Waring Blender Syndrome.JAMA Cardiology.  1:205-206. 2016
    2016 Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users.Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.  36:263-272. 2016
    2016 Addressing Stroke Risk Factors in Black and White Americans: Findings from the National Health and Nutrition Examination Survey, 2009-2010.Ethnicity and Disease.  26:9-16. 2016
    2016 Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials.PLoS ONE.  11:e0163608. 2016
    2016 Paroxysmal atrial fibrillation and the hazards of under-treatment.International Journal of Cardiology.  202:214-220. 2016
    2015 US Mortality: Influence of Race, Geography and Cardiovascular Risk Among Participants in the Population-Based REGARDS Cohort.Journal of Racial and Ethnic Health Disparities.  3:599-607. 2015
    2015 Predictors of Thromboembolic Events in Patients with Ventricular Assist Device.ASAIO Journal.  61:640-647. 2015
    2015 Race influences warfarin dose changes associated with genetic factors.Blood.  126:539-545. 2015
    2015 APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.Nephrology Dialysis Transplantation.  31:602-608. 2015
    2015 Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.American Journal of Kidney Diseases.  65:701-709. 2015
    2015 Genome-wide association study of warfarin maintenance dose in a Brazilian sample.Pharmacogenomics.  16:1253-1263. 2015
    2015 Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation.Circulation: Cardiovascular Quality and Outcomes.  8:8-14. 2015
    2014 Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.Blood.  124:2298-2305. 2014
    2014 Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications.Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.  34:545-554. 2014
    2014 RYR3 gene variants in subclinical atherosclerosis among HIV-infected women in the Women's Interagency HIV Study (WIHS).Atherosclerosis.  233:666-672. 2014
    2014 The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study.Frontiers in Pharmacology.  5:210. 2014
    2013 A pharmacogenetic versus a clinical algorithm for warfarin dosing.New England Journal of Medicine.  369:2283-2293. 2013
    2013 Reversal of oral anticoagulation.Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.  33:1199-1213. 2013
    2013 Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.Lancet.  382:790-796. 2013
    2013 Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study.American Journal of Kidney Diseases.  61:354-357. 2013
    2013 Pathway analysis of genome-wide data improves warfarin dose prediction.BMC Genomics.  14 Suppl 3:S11. 2013
    2013 Vitamin K intake, body mass index and warfarin maintenance dose.Cardiology.  126:214-218. 2013
    2012 Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension.Journal of Clinical Hypertension.  14:694-700. 2012
    2012 Use of secondary prevention medications among adults with reduced kidney function.Clinical Journal of the American Society of Nephrology.  7:604-611. 2012
    2012 Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy.Thromb Haemost.  107:232-240. 2012
    2012 Warfarin pharmacogenetics: challenges and opportunities for clinical translation.Frontiers in Pharmacology.  3:183. 2012
    2011 High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans.Computer applications in the biosciences : CABIOS.  27:1384-1389. 2011
    2011 Preference-based quality-of-life measures for neocortical epilepsy surgery.Epilepsia.  52:1018-1020. 2011
    2011 Controlling Population Structure in Human Genetic Association Studies with Samples of Unrelated Individuals.Statistics and Its Interface.  4:317-326. 2011
    2011 Practical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate.Statistics and Its Interface.  4:339-352. 2011
    2010 Warfarin dosing in patients with impaired kidney function.American Journal of Kidney Diseases.  56:823-831. 2010
    2010 Expectations, validity, and reality in pharmacogenetics.Journal of Clinical Epidemiology.  63:960-969. 2010
    2010 Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.Blood.  115:3827-3834. 2010
    2010 Integration of genetic, clinical, and INR data to refine warfarin dosing.Clinical Pharmacology and Therapeutics.  87:572-578. 2010
    2009 Hyperammonemia following intravenous valproate loading.Epilepsy Research.  85:65-71. 2009
    2009 Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.Blood Cells, Molecules and Diseases.  43:119-128. 2009
    2009 Effect of epilepsy magnetic source imaging on intracranial electrode placement.Annals of Neurology.  65:716-723. 2009
    2009 Warfarin pharmacogenomics.Current Opinion in Molecular Therapeutics.  11:243-251. 2009
    2009 Kidney function influences warfarin responsiveness and hemorrhagic complications.Journal of the American Society of Nephrology.  20:912-921. 2009
    2009 A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.Blood Cells, Molecules and Diseases.  42:155-158. 2009
    2009 Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine.  360:753-764. 2009
    2008 VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.Pharmacogenomics.  9:1445-1458. 2008
    2008 Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics.Pharmacogenomics.  9:1331-1346. 2008
    2008 Warfarin pharmacogenetics.Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.  28:1084-1097. 2008
    2008 Functional imaging: I. Relative predictive value of intracranial electroencephalography.Annals of Neurology.  64:25-34. 2008
    2008 Functional imaging: II. Prediction of epilepsy surgery outcome.Annals of Neurology.  64:35-41. 2008
    2008 Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.Pharmacogenomics.  9:511-526. 2008
    2008 Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.Clinical Pharmacology and Therapeutics.  83:312-321. 2008
    2007 Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy.Journal of Clinical Pharmacy and Therapeutics.  32:365-371. 2007
    2007 Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.Personalized Medicine.  4:157-169. 2007
    2007 Safety of rapid intravenous loading of valproate.Epilepsia.  48:478-483. 2007
    2006 Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy.Blood Cells, Molecules and Diseases.  37:100-106. 2006
    2006 Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update.Obesity Reviews.  7:79-88. 2006
    2005 Efficacy of rapid IV administration of valproic acid for status epilepticus.Neurology.  65:500-501. 2005
    2005 Efficacy of rapid IV administration of valproic acid for status epilepticus.Neurology.  64:353-355. 2005
    2004 Superiority of fixed-dose warfarin for chronic anticoagulation.Journal of Stroke and Cerebrovascular Diseases.  13:118-121. 2004
    2003 Neurotoxicity following addition of intravenous valproate to lamotrigine therapy.Neurology.  60:1991-1992. 2003
    2001 Rasmussen's Encephalitis.Current Treatment Options in Neurology.  3:555-563. 2001
    2000 The safety of rapid valproic acid infusion.Epilepsia.  41:1342-1345. 2000


    Year Title Altmetric
    2009 Oxcarbazepine.  575-584. 2009
    2008 Warfarin Pharmacogenetics 2008
    2003 Managing Interactions: Antibiotics and antiepileptic drugs. 2003
    2000 Adverse and beneficial side effects of antiepileptic drugs 2000

    Research Overview

  • Harnessing the racial diversity of the population served at UAB, Dr. Limdi research and practice interests center around the evaluation of racial differences in the genetic underpinnings for drug response.
    1. Discovery of genetic variants and environmental factors influencing drug response
    2. Integrating clinical, genetic, socio-demographic and behavioral data to predict drug response
    3. Translating pharmacogenomic discoveries to health disparity populations
    4. Development of statistical genetic analysis approaches and methodologies
    5. Advancing Pharmacogenomics through collaborations with national and international consortia.
  • Principal Investigator On

  • Patient Oriented Research in Personalized Antithrombotic Therapy  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • Genetic and Clinical Predictors of Response to Warfarin and Novel Anticoagulants  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2019
  • Collaborative Meta-Analysis of Genetic Predictors on Warfarin Response  awarded by UNIVERSITY OF VERONA 2017 - 2018
  • Pharmacogenomic Resource for Improving Medication Effectiveness (PRIME)  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2013 - 2017
  • Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation  awarded by BOSTON MEDICAL CENTER 2010 - 2014
  • Racial Differences in Causes and Consequences of Medication Adherence  awarded by American Heart Association (Southeast Affiliate) 2014
  • Predictors of Thromboembolism and Hemorrhage in Patients on Ventricular Assist Devices  awarded by American Heart Association 2013 - 2014
  • Prediction of Warfarin Dosing Using Clinical and Genetic Factors  awarded by University of Pennsylvania 2012 - 2014
  • Clinical Site Participation in Clarification of Optimal Anticoagulation Through Genetics (COAG) Clinical Trial  awarded by University of Pennsylvania 2011 - 2014
  • Genetic and Environmental Determinants of Warfarin Response  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2008 - 2014
  • The Student Scholarship in Cardiovascular Diseases  awarded by American Heart Association 2012 - 2013
  • Private Grant  awarded by DIAGNOSTICA STAGO, INC 2012 - 2013
  • Teaching Overview

  • In addition to research and implementation, Dr. Limdi is committed to developing talent through mentorship: She brings a comprehensive and diverse set of skills, and expertise in pharmacy practice, pharmacology, pharmacogenomics, clinical research methods, epidemiology and biostatistics to didactic teaching and training residents, post-doctoral trainees and junior faculty.
  • Education And Training

  • Bachelor of Pharmacy in Pharmacy, Pharmaceutical Sciences, and Administration, Foreign University
  • Bachelor of Pharmacy in Pharmacy, Pharmaceutical Sciences, and Administration, Samford University
  • Doctor of Pharmacy, Samford University
  • Doctor of Philosophy in Epidemiology, University of Alabama at Birmingham
  • Master of Public Health, University of Alabama at Birmingham
  • Full Name

  • Nita Limdi
  • Blazerid

  • nlimdi